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Abstract 
Background 
Generalised high bone mass (HBM), associated with features of a mild skeletal dysplasia, has 
a prevalence of 0.18% in a UK DXA-scanned adult population. We hypothesized that the 
genetic component of extreme HBM includes contributions from common variants of small 
effect and rarer variants of large effect, both enriched in an extreme phenotype cohort.   
Methods 
We performed a genome-wide association study (GWAS) of adults with either extreme high 
or low BMD. Adults included individuals with unexplained extreme HBM (n=240) from the 
UK with BMD Z-scores ≥+3.2, high BMD females from the Anglo-Australasian 
Osteoporosis Genetics Consortium (AOGC) (n=1055) with Z-scores +1.5 to +4.0 and low 
BMD females also part of AOGC (n=900), with Z-scores -1.5 to -4.0.  Following imputation, 
we tested association between 6,379,332 SNPs and total hip and lumbar spine BMD Z-scores. 
For potential target genes, we assessed expression in human osteoblasts and murine 
osteocytes. 
Results 
We observed significant enrichment for associations with established BMD-associated loci, 
particularly those known to regulate endochondral ossification and Wnt signalling, 
suggesting that part of the genetic contribution to unexplained HBM is polygenic.  Further, 
we identified associations exceeding genome-wide significance between BMD and four loci: 
two established BMD-associated loci (5q14.3 containing MEF2C and 1p36.12 containing 
WNT4) and two novel loci: 5p13.3 containing NPR3 (rs9292469; minor allele frequency 
[MAF]=0.33%) associated with lumbar spine BMD and 11p15.2 containing SPON1 
(rs2697825; MAF=0.17%) associated with total hip BMD. Mouse models with mutations in 
either Npr3 or Spon1 have been reported, both have altered skeletal phenotypes, providing in 
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vivo validation that these genes are physiologically important in bone. NRP3 regulates 
endochondral ossification and skeletal growth, whilst SPON1 modulates TGF-β regulated 
BMP-driven osteoblast differentiation. Rs9292469 (downstream of NPR3) also showed some 
evidence for association with forearm BMD in the independent GEFOS sample (n=32,965). 
We found Spon1 was highly expressed in murine osteocytes from the tibiae, femora, humeri 
and calvaria, whereas Npr3 expression was more variable. 
Conclusion 
We report the most extreme-truncate GWAS of BMD performed to date. Our findings, 
suggest potentially new anabolic bone regulatory pathways that warrant further study. 
 
5 Key words 
Bone mineral density, NPR3, SPON1, endochondral ossification, Wnt signaling 
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1. Introduction 
Osteoporotic fractures are a major cause of morbidity and mortality, with associated 
healthcare costs exceeding $20 billion in the United States (1). Understanding genetic 
regulation of bone signalling pathways, which underlie the pathogenesis of skeletal disease, 
aids development of novel therapeutics to increase bone mass (2). Genome-wide association 
studies (GWAS) of bone density phenotypes, drawn mainly from general populations, have 
identified multiple BMD-associated loci, although together these only explain a relatively 
small proportion (5.8-11.8%) of variance in bone phenotypes (3, 4). An alternative approach 
is to focus on rare individuals who represent extremes of a quantitative phenotype, i.e. BMD, 
to identify variants of relatively large effect. At the very extremes, high bone mass (HBM) 
and low bone mass (LBM) occur due to monogenic mutations (e.g. in SOST, LRP5 or LRP4 
in HBM, and COL1A1, COL1A2, LRP5 and others in LBM); however, such monogenic 
disorders fail to explain the vast majority of individuals with either HBM or LBM (5). 
Conceivably, extreme HBM or LBM may both constitute polygenic conditions, either 
explained by variants in the same genes that determine BMD in the general population (3), or 
in novel extreme bone mass genes. In support of this, a previous GWAS of a moderate high 
and low BMD population replicated associations in 21 loci previously established to be 
BMD-associated from analyses of normal populations and identified six new genetic 
associations, highlighting the efficiency of extreme-truncated selection for quantitative trait 
GWAS design (6). Such augmentation of statistical power through analysis of extreme 
phenotypes has been advantageous in a range of clinical phenotypes (7-10) and is an 
established approach to investigate complex disease (11, 12). 
Unexplained generalised HBM has a prevalence of 0.18% amongst a UK DXA-scanned adult 
population; affected individuals also have features suggestive of a mild skeletal dysplasia, 
such as mandibular enlargement and enthesophytes  (13, 14). We hypothesized that 
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unexplained extreme HBM is genetically determined by variation in both established and 
novel BMD loci. In this GWAS of individuals with unexplained extreme HBM, we aimed to 
first determine whether variants in known loci account for BMD variation in this population. 
Secondly, we aimed to identify novel loci and validate the use of extreme BMD populations 
for genetic discovery. We augmented our unexplained extreme HBM population with a 
further moderate high BMD population and made comparison with an extreme-low BMD 
population to enhance statistical power. We investigated associated gene expression using 
human osteoblast expression quantitative trait loci (eQTL) and novel murine osteocyte 
expression data. 
 
2. Methods 
We investigated three populations to identify genetic determinants of unexplained high BMD 
(Fig. 1, Supplementary Table 1). Individuals included: (1) UK-based unexplained extreme 
HBM index cases (n=240) with total hip (TH) or first lumbar vertebra (L1) Z-score ≥+3.2; 
(2) more moderate high BMD females from the Anglo-Australasian Osteoporosis Genetics 
Consortium (AOGC) (n=1055) with TH Z-scores between +1.5 and +4.0 (3) low BMD 
females also part of AOGC (n=900), with TH Z-scores between -1.5 and -4.0, representing an 
extreme-low ‘super-control’ group, enhancing statistical power. Australian individuals who 
self-identify as Caucasian have been shown to be representative of UK populations regarding 
population stratification (6). 
2.1.1. High Bone Mass Cases (Supplementary Methods) 
The HBM study is a UK based multi-centred observational study of adults with unexplained 
HBM, identified incidentally on routine clinical DXA scanning. Full details of DXA database 
screening and participant recruitment have previously been reported (13). In brief, DXA 
databases containing 335,115 DXA scans were initially searched for a BMD T or Z-score 
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≥+4 at any site within the lumbar spine (LS) or hip, at UK 13 centers. All 1505 DXA images 
were visually inspected; 962 cases with established and/or artefactual causes of raised BMD 
were excluded, taking particular care to exclude osteoarthritic artefacts affecting the lumbar 
spine (see Supplementary Methods 1). A generalized HBM trait would be expected to affect 
both spine and hip BMD, though not necessarily to the same extent. Hence, we refined the 
definition of HBM index cases as a) L1 Z-score of ≥ +3.2 plus TH Z-score of ≥ +1.2 and/or 
b) TH Z-score ≥ +3.2 plus L1 Z-score of ≥ +1.2 (using age and gender-adjusted BMD Z-
scores). A threshold of +3.2 was in keeping with the only published precedent for identifying 
HBM previously described using DXA (15), and these threshold combinations most 
appropriately differentiated generalized HBM from artefact. Z rather than T-score was used 
to limit age bias. Of 533 unexplained HBM index cases invited to participate, 248 (47%) 
were recruited between 2008-10 (13), aged 18-90 years. After Sanger sequencing all HBM 
index cases, we excluded seven with LRP5 mutations and one who carried a SOST mutation 
(5), leaving 240 unexplained HBM individuals for GWAS. 
This study was approved by the Bath Multi-centre Research Ethics Committee (REC: 
05/Q2001/78) and at each NHS Local REC. 
2.1.2. Anglo-Australasian Osteoporosis Genetics Consortium (AOGC) High BMD Cases 
and Low BMD Controls (Supplementary Methods) 
The AOGC population included 1128 Australian, 74 New Zealand and 753 British women, 
aged between 55–85 years, five or more years postmenopausal, with either moderate high 
BMD (age and gender-adjusted BMD Z-scores of +1.5 to +4.0, n=1055) or low BMD (age- 
and gender-adjusted BMD Z-scores of -4.0 to -1.5, n=900) (6) (Fig. 1). Low BMD controls 
were excluded if they had secondary causes of osteoporosis (as previously described (6)). 
The AOGC study was approved by the Queensland Office of Human Research Ethics 
Committee (Ref:2008/018), the University of Queensland (Ref:200800376) and/or relevant 
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research ethics authorities at each participating centre. Some participants were recruited 
through genetic and/or clinical studies (all with appropriate ethical approval) but also 
provided written informed consent to contribute to collaborative genetic studies (16-18). 
 
Fig. 1 
 
Fig. 1; Flow diagram explaining recruitment of study populations with BMD data availability 
enabling lumbar spine (LS) and total hip (TH) GWAS (Stage 1). BMD; Bone Mineral 
Density. AOGC; Anglo-Australasian Osteoporosis Genetics Consortium. QC; Quality Control 
steps including exclusion of ethnic outliers 
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2.2. Genotyping and Quality Control 
SNP genotyping was performed using Infinium OmniExpress-12v1.0 for the UK unexplained  
HBM cases (n=240); and Illumina Infinium II HumHap300 (n=140), 370CNVDuo (n=4), 
370CNVQuad (n=1882) and 610Quad (n=10) chips for the AOGC high and low BMD 
individuals (n=2036), at the University of Queensland Diamantina Institute, Brisbane, 
Australia. For each study population genotype clustering was performed using Illumina's 
BeadStudio software; all SNPs with quality scores <0.15 and all individuals with <98% 
genotyping successes were excluded. Cluster plots from the 500 most strongly associated loci 
were manually inspected and poorly clustering SNPs excluded from analysis. Using PLINK, 
an IBS/IBD analysis was used to detect and exclude samples with cryptic relatedness (19). 
SNPs with minor allele frequency (MAF) <1%, those with excess missingness (>95%) and 
those not in Hardy-Weinberg equilibrium (p<1x10-6) were removed, leaving 181,323 SNPs 
in total shared across all chip types. 
2.3. Population stratification 
We used EIGENSTRAT software to detect population stratification, excluding 24 regions of 
long range linkage disequilibrium (LD) including the MHC, before running a principal 
components analysis using merged genotype data (20). Eight unexplained HBM cases were 
removed as ethnic outliers (Fig. 1). Four eigenvectors, principal components of a genetic 
covariance matrix, were used as covariates to adjust for population stratification in all GWAS 
models. 
2.4. Imputation 
Imputation analyses were conducted for all datasets separately. Phasing was carried out using 
SHAPEIT (21) and imputation with IMPUTE2 (22), using a merged 1000G/UK10K 
reference dataset as the reference set of haplotypes, enabling imputation down to MAF 0.01. 
SNPs with high imputation quality (‘info score’>0.8) were included (23); this stringent 
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threshold was used as the two populations were imputed separately. All SNPs were filtered 
for missing data <0.05, HWE 1x10-6 and MAF>0.01 (thus excluding rare HBM-causing 
monogenic disease). Additional concordance filtering was performed, excluding genotyped 
SNPs with r2<0.9 between original and masked IMPUTE2 imputed genotype, and those 
imputed SNPs in linkage disequilibrium (LD) (r2>0.2) with these excluded SNPs (24). We 
further excluded known problematic UK10K imputed SNPs (25), and SNPs not present in 
both the 1000G and UK10K cohort imputation panels. 
2.5.1. Stage 1: Genome-wide association analysis 
Association analyses for imputed genotypes were assessed with probabilistic genotypes under 
an additive (per allele) linear genetic model. Following imputation, 6,379,332 SNPs were 
tested for association in two quantitative trait analyses using the software SNPTEST. 
Quantitative analyses used genotyping data from individuals with UK unexplained HBM 
(n=232), AOGC high BMD (n=1026) and AOGC low BMD (n=852) (Fig. 1), and tested 
association between SNPs and (i) TH-BMD Z-score (combined n=2110) and (ii) LS-BMD Z-
score (combined n=1380). To explore whether genetic associations were specific to the very 
extremes of the BMD distribution, two additional quantitative analyses also tested these same 
associations restricted to the UK HBM cases (n=232) and AOGC low BMD (n=852) 
individuals again for (i) TH-BMD Z-score (n=1084) and (ii) LS-BMD Z-score (n=767). 
Quantitative models were adjusted for a priori covariates age, age2, study centre, and four 
eigenvectors. BMD Z-score was used as it standardises BMD by gender. Because gender was 
not evenly distributed within study populations (only 44 male individuals, all among 
unexplained HBM cases), inclusion as a covariate risks introducing sparse data bias (26), 
hence gender was not used as a covariate. The genomic inflation factors (λ) were 1.016 and 
0.9973 for TH-BMD and LS-BMD respectively, and 1.037 and 1.016 in the restricted 
analyses (Supplementary Fig. 1). All LocusZoom association plots included both genotyped 
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and imputed SNPs (27). In pre-planned sensitivity analyses, all quantitative models were re-
run with additional adjustment for height. Weight was not included as a covariate as 
increased android fat mass constitutes part of the unexplained HBM phenotype (28). 
To establish whether BMD-increasing alleles were enriched in unexplained HBM, we 
performed a case-control GWAS of HBM cases versus unselected control individuals from 
the well described second Wellcome Trust Case Control Consortium (WTCCC2) (n=5667) 
representing the general population, in whom BMD whilst unmeasured, is considered to be 
normal (29). 
2.5.2. Stage 2: Replication in GEFOS 
We used publicly available data from the GEFOS 2015 meta-analysis (n=32,965) of whole-
genome sequencing, whole-exome sequencing, and deep imputation of genotype data 
(www.gefos.org/?q=content/data-release-2015) for S Ps associated with femoral neck (FN), 
LS and forearm BMD (chiefly distal radius measured), which had been adjusted for age, age2, 
gender and weight (30). As the AOGC cohort had contributed to the GEFOS meta-data, the 
GEFOS 2015 meta-analysis was rerun excluding AOGC data (n=30,970), with results used to 
assess replication of SNPs surpassing GWA significance (p<5x10-8) in Stage 1. 
2.5.3. Stage 3: Gene expression 
2.5.3.1 Gene expression in primary human osteoblasts 
To assess whether identified variants were involved in the regulation of messenger RNA 
levels via eQTLs, we performed cis-eQTL analyses of SNPs surpassing the GWA threshold 
(p<5x10-8) in 95 primary human osteoblasts (as described previously (31); GEO reference 
GSE15678), using genome-wide SNP data imputed to the combined UK10K and 1000G 
Phase 1 v3 reference panel (23). Using α=0.05 with Bonferroni correction, we aimed to 
identify gene targets for novel SNPs identified in Stage 1 (n=4) and SNPs in LD (n=31; 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Page 12 of 40 
 
r2>0.8), by examining gene expression profiles of all genes within 1Mb of each lead SNP 
(included 24 gene probes). 
2.5.3.2. Gene expression in murine osteocytes 
Osteocyte expression was determined through an analysis of whole transcriptome sequencing 
data from the primary osteocytes of four different bone types (tibia, femur, humerus and 
calvaria) from mice (marrow removed, 16 week old female mice, strain C57BL6/NTac, n=8 
per bone) (32). RNA-sequencing reads were trimmed of low quality data using trimgalore 
(33), aligned to the GRCm38.p3 genome guided by the GENCODE M5 transcriptome 
annotation (34) using STAR (35) and expression quantified using RSEM (36). A threshold of 
gene expression was determined based on the distribution of FPKM-normalised (Fragments 
Per Kilobase per Million mapped reads) gene expression for each sample (37). “Expressed” 
genes were above this threshold for all 8 of 8 replicates in any bone type. Osteocyte enriched 
expression of these genes in the skeleton was determined by comparing transcriptome-
sequencing data from bone-samples with osteocytes isolated versus those samples with 
marrow left intact (10-week old male mice, strain C57BL6/NTac, n=5 per group) (32). 
 
3. Results 
3.1.1. Stage 1: Analyses concerning established BMD-associated loci 
In total, 49 of 64 SNPs previously associated at GWAS significance level with DXA BMD 
and/or fracture by Estrada et al (3) were available in our imputed dataset (15 were not as they 
were either not imputed (n=6), on chromosome X (n=1), or were excluded by filtering for 
concordance (n=7) or infoscore (n=1)). The previously identified lead SNP at the MEF2C 
locus was associated with TH BMD at genome-wide significance (p<5x10-10), and lead SNPs 
at WNT4/ZBTB40, SOX6 and CTNNB1 loci were strongly suggestive of association (p<1x10-
6).  Overall, 29 of the available SNPs (59%) were associated with BMD at p<0.05 
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(Supplementary Table 2). QQ plots of p values for the 49 tested SNPs assessing association at 
either TH or LS BMD (Supplementary Fig. 2) showed enrichment for known BMD-
associated loci (i.e. observed p values were much smaller than those expected). However, to 
determine whether this enrichment is explained by excess variation in common BMD-
increasing alleles and/or BMD-decreasing alleles, we ran two case-control GWAS’ (Fig. 2). 
The first compared unexplained HBM cases against AOGC low BMD controls confirming 
the enrichment seen in quantitative GWAS. The second compared unexplained HBM cases 
against WTCCC2 controls considered to have normal BMD, confirming that unexplained 
HBM is polygenic reflecting enrichment at known common BMD-associated loci (Fig. 2).  
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Fig. 2 
 
 
 
Fig. 2; QQ plot for p values for 49 established BMD-associated loci in Case-Control GWAS 
of (A) unexplained HBM cases vs. AOGC low BMD controls, and (B) unexplained HBM 
cases vs. the second WTCCC2 (Wellcome Trust Case Control Consortium) controls. In both 
plots, the strength of observed associations for many SNPs far exceeded expected values. 
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As expected, βs for BMD measured at both the TH and LS were substantially larger in this 
HBM GWAS compared to the published general population GWAS from GEFOS (3); all 
directions of effect were consistent (Supplementary Table 2), including when analysis was re-
run including additional co-variates of gender and weight (Supplementary Table 3). 
3.1.2. Stage 1: GWAS discovery findings 
Our quantitative trait analyses identified SNPs at four loci that surpassed a genome-wide 
significant threshold (p<5x10-8) (Table 1, Supplementary Fig. 3). Two loci, near NPR3 and 
within SPON1, have not been implicated in GWAS of BMD previously, whereas MEF2C and 
WNT4/ZBTB40 loci represent established BMD-associated regions (3) (Supplementary Figs. 
4a & 4b). MEF2C and WNT4/ZBTB40 loci were most strongly associated with TH-BMD Z-
score, as was SPON1 in analyses restricted to unexplained HBM and AOGC low-BMD 
individuals, suggesting this association may be specific to extreme BMD (rs2697825 lies 
within intron 3 of SPON1, Fig. 3).  The NPR3 locus was most strongly associated with LS-
BMD Z-score (rs9292469 is 48.5kb 3’of NPR3 with the LD block including part of this gene) 
(Fig. 4). As a SNP in the NPR3 locus has previously been associated with adult height and 
truncal length (38), we re-ran our GWAS model with additional height adjustment; however, 
this did not attenuate our identified association (β 0.23, p=2.25x10-8) (Supplementary Table 
4, Supplementary Fig. 5). Height adjustment did however partially attenuate the association 
between rs2697825 (within the SPON1 locus) and TH-BMD Z-score (Supplementary Table 
4). We further identified 75 loci suggestive for association (p<5x10-5) with TH-BMD and 71 
with LS-BMD (Supplementary Tables 5 & 6). Results were unchanged in a sensitivity 
analysis excluding the 48 men (data not shown). 
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Table 1: Stage 1 - Genome-wide significant SNPs with p<5x10
-8
 associated with BMD Z-score measured at the total hip and lumbar spine  
 
rsID Locus Position 
Closest 
gene / 
candidate 
EA EAF Total Hip BMD Z-score Lumbar Spine BMD Z-score 
      n β SE p n β SE p 
rs1366594 5q14.3 88376061 MEF2C C 0.47 2110 -0.191 0.031 4.83x10
-10
 1380 -0.103 0.039 7.85x10
-3
 
rs113784679 1p36.12 22648479 
WNT4/ 
ZBTB40 
T 0.04 2110 0.511 0.088 8.40 x10
-9
 1380 0.215 0.115 6.19x10
-2
 
rs9292469 5p13.3 32840210 NPR3 T 0.33 2110 0.108 0.033 1.00x10
-3
 1380 0.232 0.041 2.70 x10
-8
 
rs2697825 11p15.2 14089431 SPON1 G 0.17 1084
a
 0.310 0.056 4.93 x10
-8
 767
a
 0.188 0.065 3.92x10
-3
 
 
Chromosome position using: GRCh37.p13 
Quantitative analysis results shown use data from HBM, AOGC high BMD and AOGC low BMD cohorts, except 
a 
which reflects analyses restricted to HBM and AOGC low 
BMD cohorts. Model is adjusted for age, age
2
, centre and 4 PCs 
p < 5 x 10
-8
 appear in bold 
EA: Effect Allele (BMD increasing); EAF: Effect Allele Frequency. SE: Standard Error. β: effect estimate – represents change in BMD Z-score per copy of the SNP EA 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Page 16 of 40 
 
Fig. 3 
 
Fig. 3; SPON1 regional association plot of the unexplained HBM cases and AOGC Low 
BMD controls in a quantitative trait GWAS of total hip BMD Z-Score, adjusted for age, age2 
and center (1000kb either side of rs2697825 shown). Square symbols indicate imputed SNPs; 
circles indicate those genotyped. 
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Fig. 4 
 
Fig. 4; NPR3 regional association plot of the unexplained HBM, AOGC High BMD cases 
and AOGC Low BMD controls in a quantitative trait GWAS of lumbar spine BMD Z-Score, 
adjusted for age, age2 and center (1000kb either side of rs9292469 shown). Square symbols 
indicate imputed SNPs; circles indicate those genotyped 
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3.2. Stage 2: Replication 
The four SNPs identified in Stage 1 were assessed for replication using the GEFOS 2015 
meta-analysis adjusted for age, age2, gender and weight, excluding AOGC data (Table 2). 
The MEF2C locus (rs1366594) replicated strongly in association with FN BMD, and to a 
lesser extent forearm BMD, but not with LS-BMD. The WNT4/ZBTB40 locus (rs113784679) 
also replicated in association with FN BMD, and to a lesser extent LS-BMD.  For both these 
loci the direction of association was concordant in the discovery and replication sets. The 
NPR3 locus (rs9292469) showed no association with LS-BMD, but, although not 
withstanding correction for testing 4 SNPs, was weakly associated with BMD measured at 
the forearm (p=0.0198) and FN (p=0.06), the direction of association being concordant with 
the discovery set.  The SPON1 locus (rs2697825) was associated weakly (not withstanding 
multiple testing correction) with BMD measured at the forearm (p=0.029); however, the 
direction of effect was discordant, and no association was seen at the LS or FN. 
Unfortunately, non-weight adjusted GEFOS GWAS meta-data were not available for 
replication. 
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Table 2: Stage 2 - Genome-wide significant SNPs with p<5x10
-8
 associated with BMD Z-score measured at the total hip and lumbar spine and 
replication in GEFOS 
 
rsID 
Closest 
gene / 
candidate 
EA EAF 
Stage 1: Total Hip 
BMD Z-score 
Stage 1: Lumbar 
Spine BMD Z-score 
GEFOS 
EAF 
Stage 2: GEFOS 
excluding AOGC 
FN BMD 
Stage 2: GEFOS 
excluding AOGC 
LS BMD 
Stage 2: GEFOS 
excluding AOGC 
Forearm BMD 
    Β p β p  β p β p β p 
rs1366594 MEF2C C 0.47 -0.191 4.83x10
-10
 -0.103 7.85x10
-3
 0.47 -0.073 2.93x10
-20
 -0.003 0.77 -0.077 3.40x10
-6
 
rs113784679 
WNT4/ 
ZBTB40 
T 0.04 0.511 8.40 x10
-9
 0.215 6.19x10
-2
 0.04 0.080 1.89x10
-4
 0.058 0.022 -0.002 0.97 
rs9292469 NPR3 T 0.33 0.108 1.00x10
-3
 0.232 2.70 x10
-8
 0.35 0.015 0.060 0.002 0.84 0.040 0.0198 
rs2697825 SPON1 G 0.17 0.310
 a
 4.93 x10
-8
 0.188
 a
 3.92x10
-3
 0.18 0.006 0.55 0.011 0.34 -0.046 0.0293 
 
Chromosome position using: GRCh37.p13 
Quantitative analysis results shown use data from HBM, AOGC high BMD and AOGC low BMD cohorts, except 
a 
which reflects analyses restricted to HBM and AOGC low 
BMD cohorts. Stage 1 model adjusted for age, age
2
, centre and 4 PCs. Stage 2 model GEFOS adjusted for age, age
2
, gender and weight 
Stage 1 p <5x10
-8
 appear in bold. Stage 2 p<0.05 appear in bold. 
EA: Effect Allele (BMD increasing); EAF: Effect Allele Frequency. BMD: Bone Mineral Density. FN: Femoral Neck. LS: Lumbar Spine. SE: Standard Error. β: effect 
estimate – represents change in BMD Z-score per copy of the SNP EA 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Page 20 of 40 
 
3.3. Stage 3: Gene expression 
3.3.1. Gene expression in primary human osteoblasts 
We tested the association of potential functional SNPs with cis-eQTL expression of genes in 
human osteoblasts from 95 donors (31) in whom genotype data were available and imputed to 
a combined UK10K/1000G reference panel (23). We identified potential target genes based 
on cis-eQTL evidence in human osteoblasts for two of four of our lead SNPs (Supplementary 
Table 7). Whilst rs113784679 was identified as having a potential target gene of WNT4 
(p=0.002), rs1366594 (MEF2C nearest gene) had no evidence of a target gene in osteoblasts. 
eQTL data did not support a specific gene association for rs9292469 (NPR3 nearest gene) 
(osteoclast and chondrocyte expression data were not available). SNPs in LD with rs2697825, 
which lies within an intron (3/16) of SPON1, were associated with BTBD10 expression after 
Bonferroni correction (Supplementary Tables 8 & 9). BTBD10 has not previously been 
associated with bone regulation. We assessed all SNPs lying 500kb either side of BTBD10 in 
GEFOS 2015 meta-analysis summary data; using ANNOVAR for SNP annotation 66,654 
SNPs were assessed for association with BMD (at FN, LS and forearm) (39), but no evidence 
of association was detected (all p>5x10-4). 
3.3.2. Expression of Spon1 and Npr3 in murine osteocytes  
Spon1 and Npr3 were investigated as the two genes lying closest to SNPs identified in Stage 
1. Spon1 was highly expressed in osteocytes in all four bone types forming part of a 
characteristic “osteocyte signature”, which is a list of genes significantly enriched in 
osteocytes relative to other cells in the marrow space and actively expressed in every 
replicate (Table 3).  Npr3 was expressed in osteocytes although at much lower levels than 
Spon1 and despite some variability it was actively expressed in all tibia and 7 of 8 humeri 
samples. Considering the osteoblast eQTL results, we also examined Btbd10 expression. 
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Btbd10 was expressed in whole femur, tibia, humerus and skull but its expression was not 
enriched in osteocytes. 
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Table 3: Stage 3 - Osteocyte expression by whole transcriptome sequencing of Npr3 and Spon1 in four bone types (tibia, femur, humerus 
and calvaria) from mice 
 
MGI Gene 
symbol Chrom Skeletal GO 
Tibia Femur Humerus Calvaria Clean Bone Bone And Marrow 
Expressed 
in all bone 
types 
Enriched 
in 
osteocyte 
samples 
Osteocyte 
S ignature Activity 
Mean 
FPKM Activity 
Mean 
FPKM Activity 
Mean 
FPKM Activity 
Mean 
FPKM Activity 
Mean 
FPKM Activity 
Mean 
FPKM 
Npr3 15 
GO:0001501 
GO:0002158 
GO:0033688 
Active 
8/8 
1.14 
Active 
2/8 
0.52 
Active 
7/8 
1.57 Inactive 0.24 
Active 
5/5 
1.59 Inactive 0.21 No Yes No 
Spon1 7 na 
Active 
8/8 
12.0 
Active 
8/8 
7.17 
Active 
8/8 
11.0 
Active 
8/8 
3.74 
Active 
5/5 
7.57 
Active 
5/5 
1.46 Yes Yes Yes 
 
MGI: Mouse Genome Informatics. 
Mouse Ensembl Ids: Npr3 - ENSMUSG00000022206; Spon 1 - ENSMUSG00000038156 
Skeletal GO: Gene Ontology (http://www.ebi.ac.uk) 
Activity: Number of replicates of that bone type with FPKM expression values above active gene threshold.  
Clean bone: bone with marrow removed to isolate osteocytes  
Bone and marrow: bone cleaned of connective tissue and growth plates with the marrow left intact 
Mean FPKM: Mean gene expression in for gene across samples of bone type normalised for gene length and library size (Fragment s Per Kilobase per Million mapped reads)  
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4. Discussion 
Firstly, we have identified over-representation of signal from known BMD loci, implying that 
unexplained HBM is, at least in part, polygenic in origin, influenced by common genetic 
variation. Secondly, our GWAS has identified two genome-wide significant SNPs, rs9292469 
(3’ of NPR3) and rs2697825 (within an intron of SPON1), and confirmed two established 
BMD-associated loci, MEF2C and WNT4/ZBTB40, despite our limited sample size. 
Replication of rs9292469 was only weak (concordant at distal forearm, rather than LS) and 
for rs2697825 was discordant for both site (distal forearm, rather than hip) and direction. 
However, two genes at these loci are expressed in bone, and mutations of these genes in mice 
have been shown to influence bone mineral content (BMC) (see below), giving support to 
these as novel HBM-associated genes, although further investigation is warranted. 
4.1. Established BMD-associated loci 
Of the four BMD-associated loci published by Estrada et al and identified in our analysis 
with p<5x10-5, both MEF2C (for which we found the strongest evidence of association) and 
SOX6 regulate endochondral ossification, linking this pathway to high BMD. MEF2C 
controls chondrocyte hypertrophy, cartilage ossification, and longitudinal bone growth in 
mice (40). In addition to its role in bone mass accrual during skeletal growth, endochondral 
ossification is involved in the formation of osteophytes and enthesophytes (41-43), both 
prevalent in unexplained HBM (14). This raises the possibility that variation in endochondral 
ossification pathway genes may be particularly relevant in HBM, contributing pleiotropically 
to both higher BMD and the wider associated skeletal phenotype. Besides WNT4, several 
SNPs annotated to Wnt/β-catenin signaling pathway genes (MEF2C, CTNNB1, RSPO3, and 
WLS), suggesting enhanced osteoblast activity may also contribute to the HBM phenotype. 
4.2. NPR3 (Natriuretic Peptide Receptor 3) 
The transmembrane protein NPR3 acts as a clearance receptor modulating C-type natriuretic 
peptide (CNP) activity (37, 38). The importance of natriuretic peptide (NP) signalling in bone 
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is increasingly recognised.  Natriuretic peptides ANP, BNP and CNP bind to three NP 
receptors (NPRs): ANP and BNP preferentially bind to NPR1; NPR2 to CNP; and NPR3 to 
all three NPs with similar affinity. Additionally, osteocrin, a protein secreted by osteoblast-
lineage cells with homology to NPs, also binds to NPR3 and can displace CNP, with 
subsequent enhanced signalling through NPR2 (44). NPR2 and NPR3 are both expressed in 
chondrocytes and osteoblasts (28, 37). Disrupted NP signalling results in marked skeletal 
phenotypes, with evidence from both mouse and human data.  
In humans, enhanced signalling results from autosomal dominant activating NPR2 mutations 
causing bony overgrowth and tall stature (41) (MIM# 615923). CNP overproduction causes 
bony overgrowth and childhood skeletal abnormalities, particularly affecting stature, 
vertebrae and digital length (33-36) (MIM# 600296). Mice overexpressing BNP or CNP have 
elongated bones (45, 46), as do those overexpressing osteocrin, where NPR3 clearance of 
CNP is reduced, resulting in increased NPR2 signalling (44). Multiple spontaneous and ENU 
(N-ethyl-N- nitroso urea) mouse strains with Npr3 mutations have skeletal phenotypes with 
increased linear growth, bone area and kyphosis, as endochondral ossification is delayed 
expanding the growth plate (47-50). BMC is increased in female, but not male homozygous 
ENU mice, but as bone size is also increased, BMD is normal (48). A single histological 
section, which requires further validation, has suggested trabeculae may be thicker and longer 
(49). This skeletal overgrowth due to impaired endochondral ossification is thought to result 
from increased activation of p38 MAPK signalling (47-49), which presumably delays growth 
plate quiescence. 
In contrast, in humans attenuated NP signalling from loss-of-function NRP2 mutations cause 
autosomal recessive acromesomelic dysplasia with extreme short stature (39) (MIM# 
602875); heterozygous carriers display reduced height (40) (MIM# 616255). Whilst in mice 
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lacking CNP or with loss-of-function Npr2 mutations exhibit impaired longitudinal bone 
growth (51, 52). 
In healthy adolescent humans, cross-sectional studies associate CNP synthesis with pubertal 
linear growth in, supporting its role in endochondral ossification (53). CNP is a weak 
natriuretic (54); the role of CNP/NRP3 regulation in explaining the hyponatraemia-low bone 
mass association (55) is unknown. A GWAS identified association between an NPR3 SNP 
(rs10472828) and adult height and truncal length (38); importantly additional height-adjusted 
GWAS did not alter our findings. Of note, rs9292469 was associated with heel Broadband 
Ultrasound Attenuation (BUA) in the discovery phase of a GWAS of 14,258 participants 
(p=3.1x10-6); this finding was not replicated by meta-analysis (56).  
NPR3 may be the target gene regulated by rs9292469, as our human osteoblast eQTL data do 
not support an alternative target, and we and others have shown Npr3 expression in the 
mouse skeleton (48). Previous findings in our unexplained HBM population have shown that 
although adult height is no different from controls, trabeculae are thicker increasing 
trabecular density (57, 58), possibly recapitulating observations in Npr3-mutant mice (47, 
49). Our previous analyses suggested unexplained HBM protects against age-associated 
declines in trabecular BMD (57). It is interesting that association was seen at the lumbar 
spine, and weakly replicated at the distal forearm (although not the LS); both are ‘trabecular-
rich’ sites. Taken together, our findings are consistent with previous observations of the role 
of NPR3 in regulating skeletal growth. 
4.3. SPON1 (Spondin 1/ F-spondin) 
rs2697825 is an intronic variant in SPON1. SPON1, coding for an extracellular matrix 
glycoprotein, has not previously been associated with a bone phenotype in humans. Spon1 
knockout mice have a skeletal phenotype consistent with HBM, with Spon1-/- mice at 6 
months age having 60% higher bone volume, bone volume/total volume, cortical area and 
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trabecular number with reduced trabecular spacing (59). Increased trabecular density and 
reduced endosteal expansion is seen in human HBM (57, 58). Serum CTX-1 and TRAP 
levels are normal in Spon1-/- mice; however, TGF-β1 levels are reduced compared with WT 
mice, whilst SMAD 1/5 activation is enhanced in both osteoblasts and chondrocytes (59). 
Although vertebrae and intramembranous bones have not been characterized in Spon1-/- mice, 
overall findings suggest reduced F-spondin activity decreases TGF-β1 levels, permiting 
activation of SMAD family transcription factors which, in conjunction with RUNX-2, 
promote BMP-driven osteoblast differentiation and hence bone formation (60). In addition to 
our observed osteocyte expression, SPON1 expression is evident in several musculoskeletal 
tissues: the embryonic growth plate cartilage, peridontal tissue and human and rodent 
osteoarthritic cartilage where SPON1 expression appears to activate TGF-β, inducing 
cartilage degradation (61-63). Surprisingly, our eQTL results suggested BTBD10 rather than 
SPON1 may be the target gene for rs2697825. BTBD10 (Broad-Complex Tramtrack Domain 
Containing 10) activates AKT by phosphorylation in neuronal and pancreatic beta cells. 
BTBD10 overexpression accelerates growth of pancreatic beta cells (64). Despite expression 
in bone, BTBD10 has no known role in bone regulation. 
The relatively high frequency of the four identified SNPs (MAFs 0.04-0.47), compared to the 
rarity of the HBM phenotype, raises the possibility that these common variants are in LD 
with rare high-effect variants. Some candidate studies in type 1 diabetes and Alzheimer’s 
disease identified stronger effects from rare variants than the common variants responsible 
for the initial identification of the associated gene(s) (65, 66). However, this is not a universal 
finding; we note the relative paucity of low frequency high-effect variants in a recent 
fractures analysis in 508,253 individuals (30). No associations of rare variants in NPR3 and 
SPON1 with BMD have been reported to date. Segregation studies show the majority of 
BMD heritability is polygenic (67-71). In specific populations, monogenic effects may be 
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observed, but always on a polygenic background (68, 71-73). The extent to which variation 
associated with NPR3 and SPON1 interacts with the enriched background polygenic 
architecture in HBM is unclear; we lacked power to assess gene-gene interactions. However, 
our ability to detect association with NPR3 and SPON1 loci, despite our relatively small 
sample size, is testament to their likely effect sizes in this unusual population. 
GWAS of the AOGC cohort alone has been published previously (6); however, associations 
with NPR3 and SPON1 loci were not identified. Only 59% of the AOGC have LS BMD 
available, so adding 232 more extreme HBM cases, in whom artefactual elevations in BMD 
were excluded, substantially increased statistical power. Moreover, the SPON1 locus was 
identified in analyses restricted to 232 unexplained HBM (+AOGC low-BMD) individuals, 
who arguably represent a more precisely defined and extreme population.   
 
4.4. Limitations 
The failure to replicate the associations of these genes at either LS or FN in the GEFOS 
(minus AOGC) cohort suggests that either there are differences in the genetic structure 
determining BMD in the extreme discovery cohort compared with the general population; 
alternately, these findings are false positives or the failure to replicate is a false negative, due 
to statistical power issues or differences in covariate handling. That the SPON1 locus was 
identified in analyses restricted to a more precisely defined and extreme population supports 
variation at this locus being more specific to HBM individuals; however, this was not the 
case for the NPR3 locus. Given the large size of the GEFOS cohort, failure to replicate even 
at nominal levels of significance, indicates that at the very least these variants do not have the 
same effect size in the general population as observed here. Distinguishing between these 
explanations requires further studies in extreme bone mass cohorts, in much larger BMD 
association databases, or in genetically modified animals. Unfortunately, no second extreme 
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BMD population currently exists, hence our use of a large general population dataset of 
DXA-measured BMD. It was not possible to re-run a non-weight adjusted GWAS for BMD 
across all GEFOS cohorts for meta-analysis. Comparisons between our study and those 
reported in the general population are hindered by these differences; we were reluctant to 
adjust for weight as this a known feature of unexplained HBM (28). Generalisability of our 
findings is limited to Caucasian females, given the small number of men in this study. 
Genotype data came from a range of platforms which introduces heterogeneity and thus could 
have biased the discovery results. Our use of stringent ‘information score’ thresholds and 
concordance filters may also have missed true associations. Lastly, whilst we included both 
osteocyte and osteoblast expression data, osteoclast and chondrocyte expression data were 
lacking. 
 
5. Conclusions 
Common variation in established BMD genes is over-represented in unexplained HBM, 
suggesting HBM is, at least in part, polygenic in origin with contribution from the same 
genes that determine BMD in the general population. Functional annotation suggested that 
genes particularly contributing to the HBM phenotype are involved in endochondral 
ossification and osteoblast differentiation and activity. Two novel BMD-associated loci have 
been identified with candidate genes NRP3 and SPON1, associated with lumbar spine and hip 
BMD respectively. These findings are supported by NRP3 and SPON1 bone expression data; 
further, both Npr3 and Spon1 have reported mouse models with altered skeletal phenotypes 
providing biological validation that these genes play a functional role in bone. Whilst small, 
our GWAS results are certainly hypothesis-generating and highlight potentially new anabolic 
bone regulatory pathways which warrant further study. 
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Highlights 
 This genome-wide association study found significant enrichment for associations 
with known BMD-associated loci, suggesting a polygenic contribution to high BMD 
 We identified a novel locus at: 5p13.3 containing NPR3 (lead SNP rs9292469) 
associated with lumbar spine BMD  
 We identified a novel locus at: 11p15.2 containing SPON1 (lead SNP rs2697825) 
associated with total hip BMD 
 Mouse models with mutations in either Npr3 or Spon1 have been reported, both have 
altered skeletal phenotypes 
 Our findings suggest potentially new anabolic bone regulatory pathways; however, 
further investigation is warranted 
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